Female Infertility Treatment Drugs Market, by Therapy, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Female infertility refers to a condition where a woman is unable to conceive after at least one year of having unprotected sex. Various factors such as age, hormone imbalance, physical health, and lifestyle can lead to female infertility. Ovulation testing, Hysterosalpingography, and ovarian reserve testing are few of the tests used to diagnose female infertility. Ovarian reserve testing is highly recommended for women over the age of 35 years. Ovulation testing involves two tests viz. Luteinizing Hormone (LH) test and Follicle-Stimulating Hormone (FSH) test to check for ovulation which can aid in finding out the cause of infertility.

Female infertility can be treated using surgical methods such as Laparoscopic or hysteroscopic surgery and Tubal surgeries. These surgeries are performed to remove or correct abnormalities to help improve chances of getting pregnant. The surgeries can be performed to correct abnormal uterine shape, removing endometrial polyps and some types of fibroids that misshape the uterine cavity, or removing pelvic or uterine adhesions. In some cases, the fallopian tubes may be blocked or filled with fluid (hydrosalpinx). Tubal surgeries are performed to remove adhesions, dilate a tube or create a new tubal opening. Tubal surgeries are performed to remove adhesions, dilate a tube or create a new tubal opening. The global fertility rate is dropping at an alarming rate which is expected to drive the market growth of female infertility treatment drugs market over the forecast period. According to the Institute for Health Metrics and Evaluation, University of Washington, in 1950 the global fertility rate was 4.7 which halved to 2.4 in 2017 and is expected to drop as low as 1.7 in the near future.

Market Dynamics

Market players are focusing on various growth strategies such as agreements, partnerships, and collaborations to accelerate the development of drugs for infertility treatment, which is expected to boost growth of the global female infertility treatment drugs market over the forecast period. For instance, in January 2021, Bayer AG announced the expansion of their partnership with Evotec SE, a biotechnology company focusing on women health, with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS), which is one of the causes of infertility in females.

Moreover, in January 2019, Ferring Pharmaceuticals, a biopharmaceutical company entered into an exclusive agreement with Sun Pharmaceutical Industries Ltd., an India-based multinational pharmaceutical company to acquire the U.S. commercialization rights for a generic version of Ganirelix Acetate injection which is used for treatment of female infertility.

Key features of the study:

• This report provides an in-depth analysis of global female infertility treatment drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global female infertility treatment drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Ferring Pharmaceuticals, Merck & Co., Inc., Bayer AG, Abbott Laboratories, Par Pharmaceutical, Inc., Sumitovant, Livzon, Zydus Cadila, Oxolife, and Mankind Pharma
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global female infertility treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the female infertility treatment drugs market

Detailed Segmentation:

• Global Female Infertility Treatment Drugs Market, By Therapy:
  • Gonadotropins
  • Clomiphene
  • Letrozole
  • Metformin
  • Leuprolide Acetate
  • Bromocriptine
  • Estrogens
  • Ganirelix Acetate
  • Cetrotide Acetate
  • Progesterone
• Global Female Infertility Treatment Drugs Market, By Route of Administration:
  • Oral
  • Injectable
• Global Female Infertility Treatment Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Female Infertility Treatment Drugs Market, By Region:
  • North America
• By Therapy:
  • Gonadotropins
  • Clomiphene
  • Letrozole
  • Metformin
  • Leuprolide Acetate
  • Bromocriptine
  • Estrogens
  • Ganirelix Acetate
  • Cetrotide Acetate
  • Progesterone
• By Route of Administration:
  • Oral
  • Injectable
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • U.S.
  • Canada
  • Latin America
• By Therapy:
  • Gonadotropins
  • Clomiphene
  • Letrozole
  • Metformin
  • Leuprolide Acetate
  • Bromocriptine
  • Estrogens
  • Ganirelix Acetate
  • Cetrotide Acetate
  • Progesterone
• By Route of Administration:
  • Oral
  • Injectable
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
• By Therapy:
  • Gonadotropins
  • Clomiphene
  • Letrozole
  • Metformin
  • Leuprolide Acetate
  • Bromocriptine
  • Estrogens
  • Ganirelix Acetate
  • Cetrotide Acetate
  • Progesterone
• By Route of Administration:
  • Oral
  • Injectable
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
• By Therapy:
  • Gonadotropins
  • Clomiphene
  • Letrozole
  • Metformin
  • Leuprolide Acetate
  • Bromocriptine
  • Estrogens
  • Ganirelix Acetate
  • Cetrotide Acetate
  • Progesterone
• By Route of Administration:
  • Oral
  • Injectable
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
• By Therapy:
  • Gonadotropins
  • Clomiphene
  • Letrozole
  • Metformin
  • Leuprolide Acetate
  • Bromocriptine
  • Estrogens
  • Ganirelix Acetate
  • Cetrotide Acetate
  • Progesterone
• By Route of Administration:
  • Oral
  • Injectable
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
• By Therapy:
  • Gonadotropins
  • Clomiphene
  • Letrozole
  • Metformin
  • Leuprolide Acetate
  • Bromocriptine
  • Estrogens
  • Ganirelix Acetate
  • Cetrotide Acetate
  • Progesterone
• By Route of Administration:
  • Oral
  • Injectable
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region/Country:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
• Ferring Pharmaceuticals*
  • Company Highlights
  • Therapys Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
• Bayer AG
• Abbott Laboratories
• Par Pharmaceutical, Inc.
• Sumitovant
• Livzon
• Zydus Cadila
• Oxolife
• Mankind Pharma

"*" marked represents similar segmentation in other categories in the respective section.